In vitro activities of the des-fluoro(6) quinolone BMS-284756 against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections

被引：17
|
作者：
Goldstein, EJC
Citron, DM
Merriam, CV
Warren, YA
Tyrrell, KL
Fernandez, H
机构：
[1] Univ Calif Los Angeles, Med Ctr, RM Alden Res Lab, Santa Monica, CA 90404 USA
[2] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90073 USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2002年 / 46卷 / 03期
关键词：
D O I：
10.1128/AAC.46.3.866-870.2002
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
BMS-284756, a new des-fluoro(6) quinolone, was very active against 240 aerobic and 180 anaerobic isolates from bite victims. It inhibited 403 of 420 (96%) isolates, including those of Maraxella spp., CDC group EF-4, and Eikenella corrodens at less than or equal to2 mug/ml and those of all Pasteurella spp. and Bergeyella zoohelcum at less than or equal to0.015 mug/ml. Fusobacterium russii and 6 of 11 Fusobacterium nucleatum isolates of animal bite origin were resistant, but isolates of human bite origin were susceptible, which suggests that they were of a different subspecies.
引用
收藏
页码：866 / 870
页数：5
相关论文
共 25 条
  • [1] Comparative in vitro activities of ABT-773 against aerobic and anaerobic pathogens isolated from skin and soft-tissue animal and human bite wound infections
    Goldstein, EJC
    Citron, DM
    Merriam, CV
    Warren, Y
    Tyrrell, K
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) : 2525 - 2529
  • [2] Activity of the novel des-fluoro(6) quinolone BMS-284756 against methicillin-susceptible and -resistant staphylococci
    Fung-Tomc, J
    Valera, L
    Minassian, B
    Bonner, D
    Gradelski, E
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (05) : 735 - 738
  • [3] In vitro activity of a novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), against rapidly growing mycobacteria and Nocardia isolates
    Valera, L
    Gradelski, E
    Huczko, E
    Washo, T
    Yigit, H
    Fung-Tomc, J
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (01) : 140A - 142
  • [4] Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance
    Low, DE
    Muller, M
    Duncan, CL
    Willey, BM
    de Azavedo, JC
    McGeer, A
    Kreiswirth, BN
    Pong-Porter, S
    Bast, DJ
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) : 1119 - 1121
  • [5] Increased in vitro activity of the novel des-fluoro(6) quinolone BMS-284756 against genetically defined clinical isolates of Staphylococcus aureus
    Schmitz, FJ
    Boos, M
    Mayer, S
    Jagusch, H
    Fluit, AC
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (02) : 283 - 287
  • [6] In vitro activities of novel des-fluoro(6) quinolone BMS-284756 against mutants of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus selected with different quinolones
    Schmitz, FJ
    Boos, M
    Mayer, S
    Köhrer, K
    Scheuring, S
    Fluit, AC
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) : 934 - 935
  • [7] Activity of the investigational des-fluoro(6)-quinolone BMS-284756 against multi-drug-resistant isolates of Streptococcus pneumoniae
    Jorgensen, JH
    Crawford, SA
    Mcelmeel, ML
    Whitney, CG
    CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1166 - 1166
  • [8] Comparative in vitro activity of ertapenem and 11 other antimicrobial agents against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections
    Goldstein, EJC
    Citron, DM
    Merriam, CV
    Warren, YA
    Tyrrell, K
    Fernandez, H
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (05) : 641 - 651
  • [9] Activity of BMS-284756, a novel DES-fluoro(6)quinolone, in combination with selected antimicrobials against multi-drug resistant organisms
    Dawis, MA
    France, KA
    Isenberg, HD
    Jenkins, SG
    CLINICAL INFECTIOUS DISEASES, 2001, 33 (07) : 1166 - 1166
  • [10] Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients
    Rolston, KVI
    Frisbee-Hume, S
    LeBlanc, BM
    Streeter, H
    Ho, DH
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 44 (02) : 187 - 194
123